# EDGAR Filing Document

**Accession Number:** 0001684144
**File Stem:** 0001654954-23-003129
**Filing Date:** 2023-3
**Character Count:** 39492
**Document Hash:** 6640615ed7783cc426f32cb16f5937aa
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001654954-23-003129.hdr.sgml**: 20230317

**ACCESSION NUMBER**: 0001654954-23-003129

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 19

**CONFORMED PERIOD OF REPORT**: 20230315

**ITEM INFORMATION**: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20230317

**DATE AS OF CHANGE**: 20230317

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Zomedica Corp.
- **CENTRAL INDEX KEY:** 0001684144
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 000000000
- **STATE OF INCORPORATION:** A0
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-38298
- **FILM NUMBER:** 23742760

**BUSINESS ADDRESS:**
- **STREET 1:** 100 PHOENIX DRIVE
- **STREET 2:** SUITE 125
- **CITY:** ANN ARBOR
- **STATE:** MI
- **ZIP:** 48108
- **BUSINESS PHONE:** (734) 369-2555

**MAIL ADDRESS:**
- **STREET 1:** 100 PHOENIX DRIVE
- **STREET 2:** SUITE 125
- **CITY:** ANN ARBOR
- **STATE:** MI
- **ZIP:** 48108

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Zomedica Pharmaceuticals Corp.
- **DATE OF NAME CHANGE:** 20160908

?xml version="1.0" encoding="utf-8"?zom_8k.htm

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

_______________________________

**FORM 8-K**

_______________________________

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): March 15, 2023**

_______________________________

---

| |
|:---|
| **ZOMEDICA CORP.** |
| (Exact name of registrant as specified in its charter) |

---

_______________________________

---

| | | |
|:---|:---|:---|
| **Alberta, Canada** | **001-38298** | **N/A** |
| (State or Other Jurisdiction of Incorporation) | (Commission File Number) | (I.R.S. Employer Identification No.) |

---

**100 Phoenix Drive, Suite 125**

**Ann Arbor, Michigan 48108**

(Address of Principal Executive Offices) (Zip Code)

**(734) 369-2555**

(Registrant's telephone number, including area code)

**Not Applicable**

(Former name or former address, if changed since last report)

_______________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
| Common Shares, without par value | ZOM | NYSE American |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

**Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

*Resignation of Chief Financial Officer*

On March 16, 2023, Ann Marie Cotter resigned from employment as Chief Financial Officer of Zomedica Corp. and its wholly owned subsidiary, Zomedica Inc. (collectively, the "Company"). Ms. Cotter will remain with the Company through April 15<sup>th</sup> to assist with the transition to a new Chief Financial Officer.

In connection with her resignation, Ms. Cotter entered into a separation and release agreement (the "Separation Agreement") with Zomedica Inc. Under the terms of the Separation Agreement, Ms. Cotter is entitled to receive (a) compensation through a thirty-day transition period; (b) a prorated portion of her annual cash bonus; (c) twelve (12) months of her base annual salary; and (d) acceleration of vesting for her stock options.

The Separation Agreement contains a release of claims, as well as an acknowledgment of Ms. Cotter's existing confidentiality and non-solicitation obligations with the Company (as modified by the Separation Agreement).

The foregoing description of the Separation Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Separation Agreement, a copy of which is filed as Exhibit 10.1 to this Current Report on Form 8-K and incorporated herein by reference.

*Appointment of New Chief Financial Officer*

Also on March 16, 2023, Peter Donato was appointed as the Company's Chief Financial Officer, effective immediately.

Peter Donato, age 53, has over 30 years of experience in financing, growing, and scaling companies and administrating teams. Prior to this appointment as the Company's Chief Financial Officer, Mr. Donato served as the Senior Vice President & Chief Financial Officer at Standard Bariatrics, a Cincinnati-based medical device company from May 2020 to October 2022 that was acquired by Teleflex Incorporated in a deal valued at $300 million. From April 2017 to August 2019, Mr. Donato held the position of Senior Vice President & Chief Financial Officer at Neuronetics, a Philadelphia-based transcranial magnetic stimulation therapy company, where he co-led the company's successful initial public offering. Prior to March 2017, Mr. Donato served as the Chief Financial Officer at Assurex Health, Inc., and has served as Chief Financial Officer and held other senior positions at various publicly traded health technology companies. Mr. Donato holds a Bachelor of Science in Business Administration from The Ohio State University and a Master of Business Administration degree from the University of Akron.

In connection with Mr. Donato's appointment as Chief Financial Officer, the Company agreed to pay him a base salary of $325,000 per annum. At the conclusion of each calendar year, Mr. Donato will be eligible to receive an annual discretionary bonus of up to 40% of his base salary based on the achievement of certain individual and corporate performance objectives established by the Company's Chief Executive Officer and the Board. Mr. Donato will also receive a one-time bonus amount of $35,000 upon the completion of his relocation to Michigan. Mr. Donato will be awarded options to purchase 5,000,000 common shares at an exercise price equal to the closing price of the stock on the effective date of hire. The options will vest in four equal installments, beginning on the one-year anniversary of the date of grant and will expire on the tenth anniversary of the date of grant, subject to the earlier termination upon the occurrence of certain circumstances. Mr. Donato will be eligible to participate in any employee benefits generally available to other employees. Lastly, in the event of a change of control, if Mr. Donato's employment is terminated, he will be provided a severance payment to include one year's salary and a payment equal to one year's COBRA benefits.

There is no family relationship between Mr. Donato and any director or executive officer of the Company. There are no transactions between Mr. Donato and the Company that would be required to be reported under Item 404(a) of Regulation S-K.

A copy of the offer letter extended to Mr. Donato in connection with his appointment is filed as Exhibit 10.2 to this Current Report on Form 8-K and is incorporated here by reference.

A press release announcing the events described in this Item 5.02 is furnished here as Exhibit 99.1.

**Item 9.01. Financial Statements and Exhibits.**

---

| | | |
|:---|:---|:---|
| (d)  | Exhibit No. | Description |
|  | [10.1](zom_ex101.htm) | [Separation Agreement, dated March 16, 2023, between Zomedica Inc. and Ann Marie Cotter](zom_ex101.htm) |
|  | [10.2](zom_ex102.htm) | [Offer Letter, dated March 15, 2023, between Zomedica Inc. and Peter Donato](zom_ex102.htm) |
|  | [99.1](zom_ex991.htm) | [Press Release, dated March 16, 2023](zom_ex991.htm) |
|  | 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |

---

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **ZOMEDICA CORP.** | **ZOMEDICA CORP.** |
| Date: March 17, 2023 | By:  | /s/ Karen DeHaan-Fullerton |
|  | Name:<br>Title:  | Karen DeHaan-Fullerton<br>General Counsel |

---

**EXHIBIT INDEX**

---

| | | |
|:---|:---|:---|
| (d)  | Exhibit No. | Description |
|  | [10.1](zom_ex101.htm) | [Separation Agreement, dated March 15, 2023, between Zomedica Inc. and Ann Marie Cotter](zom_ex101.htm) |
|  | [10.2](zom_ex102.htm) | [Offer Letter, dated March 15, 2023, between Zomedica Inc. and Peter Donato](zom_ex102.htm) |
|  | [99.1](zom_ex991.htm) | [Press Release, dated March 16, 2023](zom_ex991.htm) |
|  | 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |

---

## Exhibit 10.1

**EXHIBIT 10.1**

**SEPARATION AGREEMENT**

**THIS AGREEMENT** dated as of March 16, 2023 ("Agreement") is made by and between Zomedica Corp. (the "Company") and Ann Marie Cotter ("Executive").

WHEREAS, Executive is employed as the Chief Financial Officer of the Company and the Company's wholly owned subsidiary, Zomedica Inc., and

WHEREAS, the parties wish to enter into this Agreement regarding their separation, subject to the execution of the Consulting Agreement of even date (the "Consulting Agreement").

ACCORDINGLY, in consideration of the execution and delivery of this Agreement and the compliance with the promises made herein, the parties agree that the precatory clauses above are incorporated herein and further agree as follows:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. <u>Last Day of Employment</u>. Executive's last day of employment as Chief Financial Officer is March 16, 2023 and her last date of employment with the Company is April 15, 2023 (the "Separation Date").

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2. <u>Separation Benefits</u>**.** In exchange for the mutual promises made in the Agreement, the parties shall do the following:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) The Company shall compensate Executive through the Separation Date in accordance with normal payroll practices, provided that Employee performs transition services reasonably requested by Company through the Separation Date.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) The Company shall reimburse Executive for business expenses incurred through the Separation Date in accordance with the Company's policies and procedures.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) The Company shall pay Executive the prorated portion of her annual cash bonus based on thirty-five percent (35%) of base salary subject to applicable withholdings and payable no later than thirty (30) days following the Separation Date.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) The Company shall pay Executive for any accrued but unused paid time-off at the time of the next regular payroll payment following the Separation Date subject to applicable local, state, federal and social security tax withholdings.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) The Company shall pay Executive an amount equal to twelve (12) months of her three hundred thousand dollar ($300,000) base annual salary to be paid in accordance with normal payroll procedures for three (3) months following the Separation Date and the balance to be paid in a lump sum within ninety (90) days of the Separation Date subject to applicable local, state, federal and social security tax withholdings.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f) The Company and Executive agree to jointly draft a press release on her transition, characterizing it in positive terms.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g) Executive shall transition to a consulting role according to the terms of the Consulting Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(h) Notwithstanding any provisions concerning stock vesting which may be to the contrary, the Company agrees that those certain stock options granted pursuant to an Option Agreement dated March 13, 2020 and an expiration of March 12, 2025, an Option Agreement dated October 1, 2020 and an expiration of September 30, 2025, and an Option Agreement dated December 31, 2020 with an expiration of December 30, 2030 shall become immediately vested as of the Separation Date and shall be exercisable in accordance with the terms of the Company's Option Plan.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3. <u>Confidentiality</u>. Executive is subject to obligations of confidentiality pursuant to her Work Agreement dated August 27, 2018. Such obligations survive Executive's separation from service in accordance with the terms of such Work Agreement.

In addition, notwithstanding this provision or any other provision of this Agreement, Executive and the Company agree that Executive, pursuant to the Defend Trade Secrets Act of 2016, shall not have criminal or civil liability under any federal or state trade secret law for the disclosure of a trade secret that: (a) is made (i) in confidence to a federal, state, or local government official, either directly or indirectly, or to an attorney, and (ii) is made solely for the purpose of reporting or investigating a suspected violation of law; or (b) is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal. In addition and without limiting the preceding sentence, if Executive files a lawsuit for retaliation by the Company for reporting a suspected violation of law, Executive may disclose the trade secret to Executive's attorney and may use the trade secret information in the court proceeding, if Executive: (1) files any document containing the trade secret under seal; and (2) does not disclose the trade secret, except pursuant to court order.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4. <u>Confidentiality of Agreement</u>. The parties represent and agree that they will keep the negotiations surrounding this Agreement confidential, and that they will not hereafter disclose (except as required by law) any information concerning the negotiations of this Agreement to any person other than their attorneys and financial or tax advisors or, in the case of the Executive, Executive's immediate family, provided each is informed of and agrees in advance to be bound by this confidentiality provision; provided further that all parties acknowledge and agree that if applicable law requires the filing of this Agreement with the Securities and Exchange Commission ("SEC"), then no confidentiality obligation is imposed relating to any information the Company files with the SEC. Nothing in this Agreement prevents or precludes Executive from cooperating with any inquiry by the SEC or any other regulatory agency or body.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5. <u>Survival of Company Indemnification Obligations</u>. All obligations of the Company to indemnify and defend Executive, and advance fees, costs and expenses to Executive, in each case pursuant to the Indemnity Agreement dated December 28, 2022, shall survive the Executive's separation from service in accordance with the terms of such Indemnity Agreement. The Company shall not take any action that would terminate or limit the Company's obligations to indemnify Executive, including without limitation by amending its bylaws.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6. <u>Mutual Release and Waiver</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) Executive forever releases and discharges the Company, its parent, owners, agents, directors, officers, employees, and affiliates, of and from any and all claims, demands, equitable relief, damages, costs, expenses, administrative actions and causes of action of any kind or character, whether known or unknown, including, but not limited to, those claims relating in any manner to or arising from Executive's employment with the Company, or the separation thereof, or which may otherwise arise under any federal or state statute, the common law or in equity, including but not limited to any claim arising under the Americans with Disabilities Act, the Age Discrimination in Employment Act ("ADEA"), the Employee Retirement Income Security Act, the Family and Medical Leave Act, the Fair Labor Standards Act, Title VII of the Civil Rights Act of 1964, the Michigan Elliott-Larsen Civil Rights Act, or the Michigan Persons With Disabilities Civil Rights Act, all as amended, and contract or tort claims, provided that, nothing in this provision or Agreement shall preclude Executive from seeking a judicial determination regarding the validity of this waiver with respect to any claims under the ADEA..

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) The Company forever releases and discharges Executive from any claims, actions, causes of action, suits, debts, charges, complaints, claims, liabilities, obligations, promises, agreements, controversies, damages, and expenses in law or in equity, arising from or relating to Executive's employment with the Company, with the exception of claims related to fraud or embezzlement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7. <u>Non-Admission of Liability</u>. This Agreement shall not be construed as an admission, nor is it an admission, by either party that it is liable in any respect for any claim or cause of action that has been or may hereafter be asserted. This Agreement is being entered into solely for the purpose of conferring consideration upon both parties in return for their resolution of the matters enumerated above.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8. <u>Conditions of Effectiveness of this Agreement</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) <u>Right to Review Agreement.</u> Executive acknowledges and agrees that Executive has been offered a period of up to twenty-one days to review this Agreement with any attorneys, financial advisors or immediate family members, that Executive has been advised by the Company to do so, and to the extent Executive desires, has done so, that Executive has used the full twenty-one day period for such review or has voluntarily chosen to execute this Agreement before the end thereof, that Executive has read and understood the release provided herein and that Executive has knowingly and voluntarily agreed to all the terms of this Agreement and that Executive has signed this Agreement voluntarily without any coercion.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) <u>Revocation</u>. Executive has seven (7) days following the date upon which Executive signs and delivers this Agreement to the Company to revoke acceptance of the Agreement, <u>except</u> <u>that</u> the revocation shall be effective <u>only</u> <u>if</u> it is made in writing addressed to the Company and includes the statement: "I hereby revoke my acceptance of our Agreement," and such written revocation is delivered to the Company by hand, registered mail, certified mail (return receipt requested) or overnight mail at 100 Phoenix Drive, Suite 190, Ann Arbor, Michigan 48108, Attn: Larry Heaton.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9. <u>Non-disparagement</u>. The parties agree not to make or publish any statement or take any action intended to defame, disparage, humiliate, embarrass, or discredit each other or any of the other applicable Releases, their management, or their practices. Executive further agrees not to take any action that would disrupt or impair the Company's operations; provided, that this provision shall not limit or prohibit a party from taking any action required by this Agreement or the Consulting Agreement or to enforce the terms of this Agreement or the Consulting Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10. <u>Reasons for Separation</u>. The parties agree that they will in all public statements refer to the Executive's separation and the reasons therefor in a manner consistent with the press release issued in connection such termination.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;11. <u>Governing Law and Interpretation; Venue</u>. This Agreement shall be governed by the laws of the State of Michigan without regard to its conflict-of-laws principles. Any and all disputes relating to or arising out of this Agreement, Executive's employment with the Company or the termination of that employment shall be brought solely and exclusively in the federal or state courts located in Michigan.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;12. <u>No Actions</u>. Each party represents that it has not commenced, maintained, prosecuted or participated in any action, charge, complaint or proceeding of any kind (on his/its own behalf and/or on behalf of any other person and/or on behalf of or as a member of any alleged class of persons) that is pending in any court, or before any administrative or investigative body or agency (whether public, quasi-public, or private) against or involving the other party or any of his/its affiliates, including for the Company Zomedica, Inc. Each party represents that it is not aware of or participating in any effort by any person or entity to assert any action, charge, complaint or proceeding of any kind, whether in court or before an administrative body or agency (whether public, quasi-public, or private), against or involving the other party or any of his/its affiliates, including for the Company Zomedica, Inc.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;13. <u>Entire Agreement: Amendment</u>. This Agreement contains the entire understanding of the parties and supersedes all previous verbal and written agreements concerning the same subject matter, except as expressly referred to or set forth herein. This Agreement may only be modified in writing signed by both parties.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;14. <u>Return of Company Property</u>. Executive agrees to return, upon the Company's request, any Company property in her control or in her possession.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;15. <u>Negotiated Agreement</u>. This Agreement amicably resolves any issues between the parties, and they agree that this Agreement and its accompanying exhibit agreements shall neither be interpreted nor construed as an admission of any wrongdoing or liability on the part of the Company or the Executive and that neither party shall be considered the primary drafter of this Agreement or its accompanying exhibit agreements.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;16. <u>Acknowledgement</u>. The parties hereby acknowledge that they have read this Agreement, have had an adequate opportunity to review its terns and have been advised to consult with legal counsel before signing this Agreement. They further acknowledge that they understand this Agreement's terms and consequences and are executing it freely and voluntarily.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;17. <u>Binding</u>. This Agreement shall be binding upon and inure to the benefit of Executive and the Company, and their respective heirs, administrators, successors and assigns.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;18. <u>Counterparts; Facsimile and Electronic Signatures</u>. This Agreement may be executed in two or more counterparts, each of which shall be deemed to be an original and all of which together shall constitute one and the same instrument. Facsimile and electronic counterpart signatures on this Agreement shall be valid and binding.

NOW, THEREFORE, the Company and Executive now knowingly and voluntarily sign this Agreement on the date set forth below.

---

| |
|:---|
| Zomedica Corp. |
| By: |
| Printed: |
| Title: |
| Ann Marie Cotter |

---

## Exhibit 10.2

**EXHIBIT 10.2**

![](zom_ex102img1.jpg)

March 14, 2023

Peter Donato

[REDACTED]

Dear Peter:

On behalf of Zomedica Inc., I am pleased to extend an offer of employment to you for the position of Chief Financial Officer, reporting to me.

<u>Start Date.</u> Your proposed start date is March 16, 2023, or an earlier date mutually agreed upon.

<u>Base Salary.</u> Your bi-weekly salary will be $12,500.00 (equivalent to $325,000 per year). You will be eligible for annual performance-based increases in salary.

<u>Bonus.</u> You will be eligible for a bonus equal to 40% of your base salary, dependent on established company and individual goals and objectives. For 2023, you will be eligible for a full year payout (not pro-rated).

<u>Relocation Bonus.</u> Upon the completion of your relocation to Michigan, you will receive a one-time bonus in the amount of $35,000, subject to applicable tax withholding. This relocation bonus offer expires on 3/1/2024, and if earned, will be paid no later than March 15, 2024.

<u>Commuting Expenses</u>. The Company will reimburse you up to $3,000 per month for commuting expenses, upon submittal of receipts through the Company's normal expense reimbursement process, until the completion of relocation or 3/31/2024, whichever comes first. Reimbursement will in all events be paid within 30 days of the date the request for expense reimbursement is submitted and not later than March 15 of the year after the year the relevant expense is incurred.

<u>Equity Position.</u> You will be awarded an initial option to purchase 5,000,000 shares of Zomedica common stock at a strike price equal to the closing price of our stock on the later of the trading day of the formal approval of your options at a regularly scheduled meeting of the Zomedica Board of Directors or your employment date. You are eligible for an additional grant of options on your one year anniversary.

Your options will be subject to our Option Plan and our standard form option agreement which includes a four-year vesting schedule (with 25% vesting annually) for each issuance of options.

<u>Benefit Plans.</u> You will be eligible for all Zomedica benefit plans offered to Zomedica employees according to the terms of those plans, effective the first of the month following date of hire. This includes medical insurance, a 401(k) plan, and employer-paid vision, dental, short-term disability, long-term disability, and life insurance.

<u>PTO.</u> In addition to Zomedica's ten paid holidays and two floating holidays in a full calendar year, you will enjoy three weeks of PTO annually. Accrual of PTO begins on your first day of employment.

<u>Change of Control.</u> In the event that Zomedica experiences a "change of control", and you are separated from Zomedica as a result, you will be provided a severance payment to include one year's salary and a payment equal to one year's COBRA payments. Severance will be paid in a lump sum on the Company's first ordinary payroll date following your "separation from service" (within the meaning of Section 409A of the Internal Revenue Code), subject to any delay required under Treasury Regulation Section 1.409A-3(i)(2). For purposes of this letter, a "change of control" shall mean a "change of control of the Corporation" as defined in Zomedica's Amended and Restated Stock Option Plan (as in effect on the date hereof and filed with the U.S. Securities and Exchange Commission).

This offer of employment is not intended to, nor does it, constitute a contract of employment. Your employment with Zomedica Inc. will be on an at-will basis, consistent with applicable law. This offer is subject to the successful completion of background checks, and signature to a confidentiality, non-compete, and non-solicitation agreement.

With a lot of exciting work ahead of us, we're confident that you will be a key addition to both the Company and our leadership team and look forward to having you join and share in our success.

Please indicate your acceptance of this offer by signing this letter and returning it to me on or before March 15, 2023, at which time it will expire unless fully executed.

Sincerely,

Larry Heaton

CEO

**Acceptance:**

My signature below indicates I fully agree to the terms of the employment offer designated above.

 __________________________, 2023 <br> Peter Donato Date

100 Phoenix Drive, Suite 125, Ann Arbor, MI 48108 \| P: +1 734-369-2555 \| F: +1 734-436-4135 \| www.zomedica.com

## Exhibit 99.1

**EXHIBIT 99.1**

![](zom_ex991img1.jpg)<br>

**Zomedica Appoints New Chief Financial Officer**

**ANN ARBOR, MI / ACCESSWIRE / March 17, 2023** / <u>Zomedica Corp</u>. (NYSE American: ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostics and therapeutic products for companion animals, announced that it has appointed Peter L. Donato as its Chief Financial Officer, effective March 16, 2023.

Mr. Donato brings over 30 years of public and private company experience in a wide range of finance and business functions primarily in the human health sector, having held a number of senior positions from CFO, President and CEO, Executive Vice President, Senior Vice President, Vice President and Controller. Prior to joining Zomedica, Mr. Donato had a successful consulting practice specializing in public company readiness and was the Chief Financial Officer of Standard Bariatrics, a surgical company specializing in obesity surgery which was acquired by Teleflex in September of 2022. Mr. Donato has extensive experience with initial public offerings, business development and capital fund raising. Mr. Donato graduated from the Ohio State University, magna cum laude, with a BSBA in accounting and an MBA from the University of Akron, College of Business Administration.

"Peter brings a broad range of skills and experience as a public company CFO that will be increasingly important to us as we move forward," said Larry Heaton, Zomedica's Chief Executive Officer. "We are excited to welcome him to the Zomedica team."

Peter Donato commented, "Throughout my career, I've worked at public or soon-to-be public companies where I can make an impact on the business and the customers it serves. I'm excited to join Zomedica and its seasoned executive team, adding my experience to help accelerate the growth of the Company while improving the care of companion animals and the success of the veterinarians who care for them."

Mr. Donato succeeds Ann Marie Cotter, who served as Zomedica's Vice President of Finance from August 2018 until October 2020, and subsequently as Chief Financial Officer. She is retiring to pursue personal interests.

"As part of the executive team who helped transform Zomedica, Ms. Cotter's accomplishments on behalf of the Company are numerous and significant. All of us at Zomedica are appreciative of her efforts and wish her the very best as she continues to expand her horizons. I am pleased that Ann will continue to work with us for the next 30 days to ensure a smooth transition for Peter, and beyond as a consultant to provide her valuable insights as we move forward. On behalf of myself personally, our colleagues and our board of directors, I want to extend our deepest gratitude to Ann for her considerable contributions to Zomedica over the years," commented Mr. Heaton.

For additional information regarding TRUFORMA <sup>®</sup> , please click on the TRUFORMA <sup>®</sup> tab at the top of the home page on the Zomedica website (<u>www.zomedica.com</u>).

**About Zomedica**

Based in Ann Arbor, Michigan, Zomedica (NYSE American: ZOM) is a veterinary health company creating products for horses, dogs, and cats by focusing on the unmet needs of clinical veterinarians. Zomedica's product portfolio includes innovative diagnostics and medical devices that emphasize patient health and practice health. Zomedica's mission is to provide veterinarians the opportunity to increase productivity and grow revenue while better serving the animals in their care. For more information, visit <u>www.zomedica.com</u>.

**Follow Zomedica**

· Email Alerts: <u>http://investors.zomedica.com</u> 

· LinkedIn: <u>https://www.linkedin.com/company/zomedica</u> 

· Facebook: <u>https://m.facebook.com/zomedica</u> 

· Twitter: <u>https://twitter.com/zomedica</u> 

· Instagram: <u>https://www.instagram.com/zomedica_inc</u> 

**Cautionary Statement Regarding Forward-Looking Statements – Safe Harbor**

Except for statements of historical fact, this news release contains certain "forward-looking information" or "forward-looking statements" (collectively, "forward-looking information") within the meaning of applicable securities law. Forward-looking information is frequently characterized by words such as "plan", "expect", "project", "intend", "believe", "anticipate", "estimate" and other similar words, or statements that certain events or conditions "may" or "will" occur and include statements relating to our expectations regarding future results. Although we believe that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. We cannot guarantee future results, performance, or achievements. Consequently, there is no representation that the actual results achieved will be the same, in whole or in part, as those set out in the forward-looking information.

Forward-looking information is based on the opinions and estimates of management at the date the statements are made, including assumptions with respect to economic growth, demand for the Company's products, the Company's ability to produce and sell its products, sufficiency of our budgeted capital and operating expenditures, the satisfaction by our strategic partners of their obligations under our commercial agreements, our ability to realize upon our business plans and cost control efforts and the impact of COVID-19 on our business, results and financial condition.

Our forward-looking information is subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the forward-looking information. Some of the risks and other factors that could cause the results to differ materially from those expressed in the forward-looking information include, but are not limited to: the finalization of the accounting procedures necessary to report our financial results for 2022, the application of generally accepted accounting principles, which are highly complex and involve many subjective assumptions, estimates, and judgments, uncertainty as to whether our strategies and business plans will yield the expected benefits; uncertainty as to the timing and results of development work and verification and validation studies; uncertainty as to the timing and results of commercialization efforts, as well as the cost of commercialization efforts, including the cost to develop an internal sales force and manage our growth; uncertainty as to our ability to successfully integrate acquisitions; uncertainty as to our ability to supply products in response to customer demand; uncertainty as to the likelihood and timing of any required regulatory approvals, and the availability and cost of capital; the ability to identify and develop and achieve commercial success for new products and technologies; veterinary acceptance of our products; competition from related products; the level of expenditures necessary to maintain and improve the quality of products and services; changes in technology and changes in laws and regulations; our ability to secure and maintain strategic relationships; performance by our strategic partners of their obligations under our commercial agreements, including product manufacturing obligations; risks pertaining to permits and licensing, intellectual property infringement risks, risks relating to any required clinical trials and regulatory approvals, risks relating to the safety and efficacy of our products, the use of our products, intellectual property protection, risks related to the COVID-19 pandemic and its impact upon our business operations generally, including our ability to develop and commercialize our products, and the other risk factors disclosed in our filings with the SEC and under our profile on SEDAR at www.sedar.com. Readers are cautioned that this list of risk factors should not be construed as exhaustive.

The forward-looking information contained in this news release is expressly qualified by this cautionary statement. We undertake no duty to update any of the forward-looking information to conform such information to actual results or to changes in our expectations except as otherwise required by applicable securities legislation. Readers are cautioned not to place undue reliance on forward-looking information.

**Contact:**

Dave Gentry

RedChip Companies Inc.

1-800-RED-CHIP (733-2447)

Or 407-491-4498

<u>ZOM@redchip.com</u><u> </u>